Welcome to our dedicated page for Sintx Technologies SEC filings (Ticker: SINT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SINTX Technologies, Inc. filings document an advanced ceramics and biomaterials issuer focused on silicon nitride medical technologies, including formal disclosures on operating results, regulatory communications, capital formation, and governance. Recent Form 8-K reports cover quarterly financial results and Regulation FD disclosures tied to FDA 510(k) activity for silicon nitride foot and ankle medical devices.
The company’s SEC record also includes an at-the-market common stock offering agreement, officer appointment and executive compensation disclosures, and a definitive proxy statement for annual meeting voting. These filings describe board and stockholder matters, material agreements, common stock issuance mechanics, and formal disclosure topics connected to SINTX’s medical-device commercialization and biomaterials platform.
SINTX Technologies, Inc. announced that it has engaged Southern Metrics Consulting, led by medical technology executive and SINTX board member Chris Lyons, to establish and manage a new Strategic Opportunity Management Program focused on enhancing stockholder value.
The program is intended to create a disciplined, proactive framework for identifying, evaluating, prioritizing, and managing strategic opportunities that support SINTX’s long-term growth strategy. Working with executive management and the board, Southern Metrics will assess options including commercial partnerships, licensing, strategic investments, joint ventures, acquisitions, divestitures, and other corporate development initiatives. The company notes that the engagement does not indicate any specific transaction is pending and there is no assurance any opportunity will be identified, pursued, completed, or successful.
SINTX Technologies entered a letter agreement with MedTech Ceramics to clean up prior warrant-related share arrangements and modify its capital structure. The company will release 255,267 common shares from abeyance and convert the remaining 251,987 abeyance shares into a pre-funded warrant for the same number of shares, all for consideration already paid in a September 2025 transaction. An existing warrant to purchase 760,881 shares will be cancelled and replaced with a new warrant to buy 1,268,135 shares at $2.14 per share. SINTX plans to file a resale registration statement for the shares underlying the new warrant within 45 days and notes that these steps are intended to help its efforts to improve stockholders’ equity, while actual equity levels will continue to depend on its broader financial condition.
SINTX Technologies, Inc. is registering the resale of 5,819,323 shares of common stock issued in a private placement on June 2, 2026. The shares include 1,882,846 Common Shares, 3,765,692 Warrant Shares (Class A, Class B and Placement Agent Warrant Shares), and 78,212 Compensation Shares.
The company will not receive proceeds from resales by the selling stockholders; however, if the registered Warrants are exercised for cash the company would receive up to approximately $8.3 million. Shares outstanding were 6,357,630 as of June 22, 2026, rising to 10,215,895 assuming exercise of all Warrants.
The prospectus discloses Nasdaq noncompliance: stockholders’ equity of $904,000 as reported for the quarter ended March 31, 2026, and a July 6, 2026 deadline to submit a plan to regain compliance.
Sintx Technologies, Inc. files a Schedule 13G reporting beneficial ownership stakes. Laurence W. Lytton and the Lytton-Kambara Foundation each report beneficial ownership of 632,633 shares, representing 9.99% of the class. The filing notes the reported position includes 502,092 shares of Common Stock and related Class A and Class B warrants to purchase 502,092 shares. The filing cites 4,319,279 shares outstanding as of May 8, 2026 and 1,882,845 shares issued in a private placement on June 3, 2026.
SINTX Technologies reports that Stonepine entities and Jon M. Plexico jointly beneficially own 619,592 shares of Common Stock, equal to 9.9% of the class. The holdings comprise 209,205 shares and warrants to acquire 418,410 shares, subject to a 9.99% beneficial ownership limitation.
The filing cites 4,319,279 shares outstanding as of May 8, 2026 and notes 1,882,845 shares issued in a private placement referenced in a June 3, 2026 Form 8-K.
SINTX Technologies entered securities purchase agreements for a private placement of 1,882,845 units at $2.39 per unit, raising approximately $4.5 million in gross proceeds. Each unit includes one common share plus Class A and Class B warrants, each to buy one share at an exercise price of $2.14.
The warrants cover 200% of the shares issued, with Class A expiring in five years and Class B in two years and subject to revenue-based forced exercise if quarterly revenue reaches at least $2.0 million. Together with a recent $500,000 at-the-market sale, SINTX has raised about $5.0 million of equity capital, which it plans to use for working capital, commercialization, business development and other strategic opportunities.
SINTX Technologies reported that Nasdaq has notified it of noncompliance with a key listing rule. Nasdaq Listing Rule 5550(b)(1) requires at least $2.5 million in stockholders’ equity, but SINTX reported about $904,000 of stockholders’ equity as of March 31, 2026.
The company also does not meet alternative Nasdaq standards based on market value of listed securities or net income. SINTX has 45 days, until July 6, 2026, to submit a plan to regain compliance and could receive up to 180 days from the notice date if Nasdaq accepts the plan. The notice does not immediately affect the listing or trading of the common stock, and SINTX is exploring equity financing and other balance sheet initiatives, though completion is not assured.
SINTX Technologies reported Q1 2026 revenue of $380,000 and a net loss of $2.8 million, as it continues investing in commercialization of its silicon nitride medical and industrial products.
Cash fell to $1.9 million with operating cash use of $2.5 million, and accumulated deficit reached $295 million. Management highlights new FDA 510(k) clearance for the SiNAPTIC Foot & Ankle Osteotomy Wedge System and initial related revenue, plus growth in industrial applications.
However, the company states that substantial doubt exists about its ability to continue as a going concern over the next 12 months, despite cost actions, the TA&T divestiture, a sublease expected to save about $1.0 million, and remaining capacity of $5.7 million under its at-the-market equity program.
Sintx Technologies, Inc. President Robert Ryan Elmore received a grant of 4,910 shares of common stock. The shares were acquired as a compensation-related award at a reported value of $2.885 per share and are now held directly, bringing his direct ownership to 4,910 shares.